Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesCardiologyBlue Cross Blue Shield - Alabama PCSK9 Prior Auth …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - AlabamaPolicy N/A

    PCSK9 Inhibitor Prior Authorization / Request Form (Coverage Criteria)

    Customize your policy alerts

    Sign up for all blue cross blue shield - alabama policy alerts

    Know when blue cross blue shield - alabama releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is a pharmacy prior authorization/request form collecting patient, prescriber, diagnosis, treatment history, and documentation to support coverage decisions for lipid-lowering therapy (notably PCSK9 inhibitors). It affects prescribers requesting coverage or renewals from Blue Cross Blue Shield - Alabama.

    Policy Summary
    PayerBlue Cross Blue Shield - Alabama
    PolicyPCSK9 Inhibitor Prior Authorization / Request Form
    Policy CodePolicy N/A
    Change TypeInformational formno material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionProvide a completed form with patient demographics, prescriber NPI/contact, diagnosis confirmation, LDL-C within 90 days, prior therapy history, and physician signature for renewals.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12numbered clinical/questions fields
    3contact/fax/mail blocks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    90
    adherence look-back (days)
    50%LDL-C reduction threshold

    Coverage Criteria and Required Form Fields

    Coverage criteria checklist (informational — form fields)

    Information requested to establish medical necessity (form prompts provider to confirm ALL of the following as applicable):

    Diagnosis criteria: Provider must indicate diagnosis (HoFH or HeFH) and select supporting confirmation: for HoFH select any that apply — genetic confirmation of two mutant alleles (LDLR, Apo-B, PCSK9, LDLRAP1), cutaneous or tendon xanthoma before age 10, history of untreated LDL-C >500 mg/dL or treated LDL-C ≥300 mg/dL, or untreated elevated cholesterol in both parents; for HeFH select any that apply — genetic confirmation of one mutant allele (LDLR, Apo-B, PCSK9, LDLRAP1) or history of total cholesterol >290 mg/dL or LDL-C >190 mg/dL.

    From diagnostic checklist on form

    Family and clinical FH indicators: Provider must indicate presence or absence of Dutch Lipid Clinic Network score >8 and history of tendon xanthomas in the patient or first-/second-degree relatives.

    Dutch score and family xanthoma questions on form

    ASCVD events: Provider must indicate presence or absence of clinical atherosclerotic cardiovascular disease and select any qualifying events (e.g., acute coronary syndrome, MI, angina, revascularization, TIA, stroke, PAD) when relevant to the request.

    ASCVD events listed on form

    Current treatment with requested medication: Provider must state whether the patient is currently treated with the requested medication and provide start date if yes; if currently on another PCSK9 inhibitor, indicate whether that agent will be discontinued prior to starting the requested agent.

    Questions 2 and 3

    Statin therapy history: Provider must document statin use: whether patient is on high-intensity statin and adherent for the past 90 days or intolerant to high-intensity statin; if on low/moderate statin document adherence for past 90 days or intolerance defined as inability to tolerate lowest FDA starting dose to at least 2 different statins or FDA-labeled contraindication.90 days adherence look-back

    Questions 4 and 5

    LDL-C monitoring and response: Provide LDL-C value within the past 90 days and confirm whether the patient has achieved a 50% reduction in LDL-C from baseline while on a maximally tolerated statin; indicate if LDL-C has been ≥70 mg/dL in the past 90 days.LDL-C within 90 days; 50% reduction

    Questions 6 and 7

    Rationale and medication history: List reasons for selecting the requested medication (contraindications, allergies, adverse reactions, prior lower-dose trials), and provide complete prior and concurrent lipid-lowering therapies including failures.

    Question 8 and medication history fields

    Renewal requirements: For renewal requests, provider must confirm the patient has shown clinical benefit and has been adherent to the requested agent for the past 90 days and sign/date the form.90 days adherence

    Renewal section

    The form does not list any explicit exclusions. However, requests lacking required documentation will be incomplete and may not meet criteria for approval. Examples of missing information that can preclude approval include absence of a recent LDL-C value within the past 90 days, no documentation of diagnosis confirmation (clinical or genetic criteria for HoFH/HeFH), or missing details about prior and current lipid-lowering therapies. Providers should submit the completed form with all requested fields to avoid delays or denial.

    The form does not use explicit “not medically necessary” language. Instead, medical necessity is established by the presence of required clinical data: documented diagnosis criteria, recent LDL-C results, and appropriate prior therapy history. If the form does not show evidence of need—for example, no LDL-C within 90 days, no trial of or intolerance to statins, or missing information about prior PCSK9 or other lipid-lowering medication trials—the request may be determined not medically necessary.

    Laboratory Thresholds and Coding-Relevant Criteria

    LDL‑C thresholds and look‑back period
    Current LDL-C thresholdLDL-C ≥ 70 mg/dL (≥1.81 mmol/L) evaluated within the past 90 days
    Look‑back period for LDL‑C90 days — provider must supply an LDL‑C value obtained within the past 90 days
    Historical untreated HoFH thresholdHistory of untreated LDL‑C >500 mg/dL (>13 mmol/L)
    Historical treated HoFH thresholdHistory of treated LDL‑C ≥300 mg/dL (≥7.76 mmol/L)
    Historical HeFH thresholdHistory of LDL‑C >190 mg/dL (>4.9 mmol/L) or total cholesterol >290 mg/dL (>7.5 mmol/L)
    LDL‑C reduction requirement

    Prior Authorization Documentation & Provider Responsibilities

    Prior Authorization

    Prior authorization documentation requirements

    Prior authorization requests must document the patient's diagnosis and how it is confirmed: specify HoFH or HeFH and indicate supporting genetic or clinical criteria (e.g., genetic confirmation of one or two mutant alleles at LDLR/APOB/PCSK9/LDLRAP1, tendon xanthoma before age 10, or historical LDL‑C thresholds). Also include statin therapy history (intensity and adherence for the past 90 days or documented intolerance) and a current LDL‑C measured within the past 90 days.

    • Select diagnosis: HoFH or HeFH and mark confirmation method (genetic confirmation, tendon xanthoma, or specified LDL‑C thresholds).
    • Document statin therapy: high‑intensity vs low/moderate, adherence for past 90 days or intolerance (≥2 statins or FDA contraindication as applicable).
    • Provide LDL‑C value obtained within the past 90 days.
    Step Therapy

    Step therapy and trial documentation

    The form requires documentation of prior trials and failures of other lipid‑lowering therapies and a clear rationale for selecting the requested agent over alternatives; it also expects that standard statin therapy has been addressed (adherence or documented intolerance) before approval.

    Policy Background and Scope

    This prior authorization/request form is designed to assess patients with familial hypercholesterolemia (heterozygous or homozygous) or atherosclerotic cardiovascular disease who may require additional LDL-C–lowering therapy such as a PCSK9 inhibitor. It captures diagnosis confirmation, current and prior lipid-lowering treatments, adherence over the past 90 days, whether the patient achieved a 50% reduction in LDL‑C on maximally tolerated statin therapy, and whether the most recent LDL‑C is ≥ 70 mg/dL within the past 90 days. The completed form and supporting data are required to evaluate medical necessity and process the request.

    Key Diagnostic Definitions

    Homozygous familial hypercholesterolemia (HoFH) — diagnostic support
    Core diagnostic definitionHoFH: genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 loci
    Clinical diagnostic signCutaneous or tendon xanthoma before age 10 years can confirm diagnosis
    Extreme LDL‑C thresholdsHistory of untreated LDL‑C >500 mg/dL (>13 mmol/L) or treated LDL‑C ≥300 mg/dL (≥7.76 mmol/L) supports diagnosis
    Family biochemical evidenceUntreated elevated cholesterol levels consistent with HeFH in both parents (untreated LDL‑C >190 mg/dL or total cholesterol >290 mg/dL) may support HoFH diagnosis
    Heterozygous familial hypercholesterolemia (HeFH) — diagnostic support
    Core diagnostic definitionHeFH: genetic confirmation of one mutant allele at LDLR, APOB, PCSK9, or LDLRAP1 loci
    Policy Summary
    PayerBlue Cross Blue Shield - Alabama
    PolicyPCSK9 Inhibitor Prior Authorization / Request Form
    Policy CodePolicy N/A
    Change TypeInformational formno material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionProvide a completed form with patient demographics, prescriber NPI/contact, diagnosis confirmation, LDL-C within 90 days, prior therapy history, and physician signature for renewals.
    SourceLink
    On This Page
    Coverage Criteria and Required Form FieldsLaboratory Thresholds and Coding-Relevant CriteriaPrior Authorization Documentation & Provider ResponsibilitiesPolicy Background and ScopeKey Diagnostic Definitions
    Required LDL‑C reduction
    50% reduction in LDL‑C from baseline while on a maximally tolerated statin
    Assessment on therapyForm asks whether 50% reduction was achieved while patient was on a maximally tolerated statin (Yes/No)
    Documentation expectationProvider must document baseline and on‑treatment LDL‑C to verify the percent reduction
    • List prior lipid‑lowering medications tried and reasons for failure or intolerance.
    • Explain why the requested agent and dosing were chosen instead of alternatives (contraindication, allergy, adverse reaction, lower dose tried).
    • Confirm whether the patient is currently on a PCSK9 inhibitor and whether it will be discontinued before starting the requested agent.
    Documentation Required

    Required documentation to support request

    Submit the completed prior authorization form including patient demographics, prescriber information, diagnosis confirmation, prior and current lipid therapies, recent LDL‑C, treatment start date if already on the requested medication, and physician signature for renewals.

    • Patient name and date of birth; prescriber NPI/contact per form header.
    • Diagnosis confirmation details (HoFH/HeFH and selected supporting criteria).
    • List of prior and concurrent lipid‑lowering therapies and start dates; indicate if another PCSK9 inhibitor is being used and plan for discontinuation.
    • Most recent LDL‑C value within 90 days and whether a 50% reduction from baseline was achieved on maximally tolerated statin.
    • For renewals: documentation of clinical benefit and adherence for the past 90 days plus physician signature and date.
    Denial Risk

    Documentation omissions that may lead to denial

    Requests missing key elements risk denial: common omissions include absent or outdated LDL‑C (not within 90 days), lack of documented statin use/adherence or intolerance, and failure to report prior PCSK9 inhibitor use.

    • No LDL‑C value within the past 90 days or failure to indicate whether LDL‑C ≥70 mg/dL.
    • No documentation of statin therapy intensity and 90‑day adherence or documented intolerance.
    • Missing history of prior PCSK9 inhibitor use or whether it will be discontinued prior to the requested therapy.
    Biochemical criteriaHistory of total cholesterol >290 mg/dL (>7.5 mmol/L) or LDL‑C >190 mg/dL (>4.9 mmol/L) supports diagnosis
    Clinical scoringDutch Lipid Clinic Network score >8 is queried on the form as supporting evidence
    Family/tendon xanthoma historyPresence of tendon xanthomas in the patient or first/second‑degree relatives is solicited as diagnostic support